A Placebo-Controlled, Double-Blind, Cross-Over Trial of Flunarizine in Common Migraine

After four weeks of medication-free baseline observation, 29 patients with common migraine randomly received flunarizine (10 mg daily) or placebo for a 16-week period. After four weeks wash-out they crossed treatments for another 16 weeks; 27 patients completed the trial. Compared with placebo, flunarizine significantly reduced the frequency of migraine attacks and the derived headache indices, but the duration and severity of single attacks remained unchanged (Mann-Whitney U-test). The effect of flunarizine increased during the 16-week treatment period and during the last four weeks the number of migraine attacks was reduced to 50% compared to the wash-out period. The only side-effect of flunarizine was mild daytime sedation in three patients. It is concluded that flunarizine is a valuable new prophylactic agent for common migraine.

[1]  A Ward,et al.  Pentoxifylline , 1987, Drugs.

[2]  J. Olesen,et al.  Timolol vs propranolol vs placebo in common migraine prophylaxis: a double‐blind multicenter trial , 1984 .

[3]  R. N. Brogden,et al.  Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. , 1984, Drugs.

[4]  Martin Lauritzen,et al.  Changes in regional cerebral blood flow during the course of classic migraine attacks , 1983, Annals of neurology.

[5]  E. Spierings,et al.  Comparison of Flunarizine (Sibelium®) and Pizotifen (Sandomigran®) in Migraine Treatment: A Double-Blind Study , 1982, Cephalalgia : an international journal of headache.

[6]  W. Amery,et al.  Brain Hypoxia: The Turning-Point in the Genesis of the Migraine Attack? , 1982, Cephalalgia : an international journal of headache.

[7]  P. Turner,et al.  β-Adrenoceptor Blockade and Migraine , 1982 .

[8]  P. Turner,et al.  Beta-adrenoceptor blockade and migraine. , 1982, Cephalalgia : an international journal of headache.

[9]  P. Louis.  A Double‐blind Placebo‐controlled Prophylactic Study of Flunarizine (Sibelium®) in Migraine , 1981, Headache.

[10]  J. Olesen,et al.  Methodological Aspects of Prophylactic Drug Trials in Migraine , 1981, Cephalalgia : an international journal of headache.

[11]  J. Olesen,et al.  THE COMMON MIGRAINE ATTACK MAY NOT BE INITIATED BY CEREBRAL ISCHAEMIA , 1981, The Lancet.

[12]  J. Olesen,et al.  Focal hyperemia followed by spreading oligemia and impaired activation of rcbf in classic migraine , 1981, Annals of neurology.

[13]  W. Girke,et al.  [Results of treatment of migraine patients with cinnarizine and flunarizine]. , 1980, Die Medizinische Welt.

[14]  E. Boisen,et al.  Clonidine in the prophylaxis of migraine , 1978, Acta neurologica Scandinavica.

[15]  G G Koch,et al.  The use of non-parametric methods in the statistical analysis of the two-period change-over design. , 1972, Biometrics.

[16]  R. Ryan.  BC‐105 A NEW PREPARATION FOR THE INTERVAL TREATMENT OF MIGRAINE‐A DOUBLE BLIND EVALUATION COMPARED WITH A PLACEBO , 1971, Headache.

[17]  O. Sjaastad,et al.  APPRAISAL OF BC‐105 IN MIGRAINE PROPHYLAXIS , 1969, Acta neurologica Scandinavica.

[18]  E. Skinhøj,et al.  Regional blood flow in internal carotid distribution during migraine attack. , 1969, British medical journal.